GlassScriptPhysician profile
Thomas D Mulgrew
NPI 1457452070
$3,291.26
in general payments reported to CMS, 2019-2025
40 companies · $1,112 in 2025
The $1,112 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $352 · 2020: $41.14 · 2021: $244 · 2022: $197 · 2023: $624 · 2024: $721 · 2025: $1,112.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,357 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,356.70 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $541.41 | 2019-2025 | Mavenclad |
| Abbvie INC. | $305.97 | 2021-2025 | |
| Harmony Biosciences LLC | $201.03 | 2021-2025 | Wakix |
| Argenx US, INC. | $200.05 | 2023-2025 | Vyvgart Hytrulo, Vyvgart |
| Biogen, INC. | $147.93 | 2021-2025 | Vumerity, Tysabri, Leqembi |
| Lundbeck LLC | $145.19 | 2024-2025 | Vyepti, Rexulti |
| Genentech USA, INC. | $139.33 | 2019-2025 | Ocrevus, Ocrevus Zunovo |
| Ucb, INC. | $130.25 | 2020-2025 | Briviact |
| Genzyme Corporation | $127.53 | 2019-2025 | |
| Pfizer INC. | $125.39 | 2023-2025 | |
| Teva Pharmaceuticals USA, INC. | $111.31 | 2019-2025 | Austedo Xr, Austedo Xr |
| Jazz Pharmaceuticals INC. | $106.42 | 2019-2025 | |
| Neurelis, INC. | $101.27 | 2023-2024 | Valtoco |
| Tg Therapeutics, INC. | $94.26 | 2024-2025 | |
| Eisai INC. | $73.43 | 2023-2025 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Mulgrew listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.